Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Romiplostim for Oral TPO-RA Resistant ITP

A legfontosabb adatok

Ki végzi
The First Affiliated Hospital of Soochow University
Hol
Suzhou (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
60 fő, tervezett
Kezdés
2026. márc. 15.
Várható befejezés
2028. jún.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Romiplostim
A regiszteradat frissítve
2026. május 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary immune thrombocytopenia (ITP) whose oral TPO-RA pills did not work, stopped working or could not be tolerated. They will get weekly romiplostim injections.

Életkor
18 years or older
Nem
All sexes
A betegség stádiuma
Primary ITP, diagnosed by current guidelines. Platelet count below 30×10⁹/L on at least two tests, ≥5 days apart. ECOG performance status 0-2 (able to care for yourself at least).
Korábbi kezelés
Must have failed eltrombopag, hetrombopag or avatrombopag. Failure means: platelets stayed below 30×10⁹/L after ≥4 weeks at the highest allowed or tolerated dose, or a response (≥50×10⁹/L) was lost with platelets below 30×10⁹/L on two visits ≥1 week apart, or the drug was stopped because it was not tolerated. Cannot have had romiplostim before. No rituximab or other B-cell depleting therapy within 6 months. No immunosuppressants within 4 weeks. No spleen removal within 8 weeks. No prednisone >10 mg/day or IVIG within 2 weeks.
Biomarker vagy leletérték
Baseline platelet count below 30×10⁹/L.

A részvétel fő kizáró okai

  • ITP caused by another illness, a drug or an infection such as HIV/HCV/HBV
  • Blood clot, heart attack or stroke within 6 months, or a known clotting disorder
  • Bone marrow scarring (MF grade ≥2) or known reticulin fibrosis
  • Severe liver or kidney problems, or NYHA class III or IV heart failure
  • Cancer within 5 years (some exceptions), pregnancy or breastfeeding

A regiszter feltételei, szó szerint

Mind a 4 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years Diagnosed with primary immune thrombocytopenia (ITP) according to current guidelines
  • Failed prior oral TPO-RA therapy (eltrombopag, hetrombopag, or avatrombopag), defined as:
  • Platelet count persistently <30×10⁹/L after ≥4 weeks of treatment at the maximum recommended or tolerated dose, OR Prior achieved response (platelet ≥50×10⁹/L) then lost response with platelet count <30×10⁹/L on two consecutive visits (≥1 week apart), OR Intolerance to oral TPO-RA leading to discontinuation (with documented reason) Baseline platelet count <30×10⁹/L (at least two measurements, ≥5 days apart) ECOG performance status 0-2 Willing and able to receive weekly subcutaneous injections and comply with study procedures For women of childbearing potential: negative pregnancy test at screening and agreement to use effective contraception during the study and for 3 months after the last dose Able to provide written informed consent

Ki nem vehet részt

  • Secondary ITP (e.g., associated with autoimmune diseases, lymphoproliferative disorders, drug-induced, or infections such as HIV/HCV/HBV) Known hypersensitivity to romiplostim or any of its excipients Prior treatment with romiplostim Received rituximab or other B-cell depleting therapy within 6 months prior to screening Received immunosuppressants (e.g., cyclosporine, mycophenolate mofetil, azathioprine, danazol) within 4 weeks prior to screening Splenectomy within 8 weeks prior to screening Use of corticosteroids (prednisone >10 mg/day or equivalent) or IVIG within 2 weeks prior to screening History of bone marrow fibrosis (MF grade ≥2) or known reticulin fibrosis History of arterial or venous thromboembolic event (e.g., myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism) within 6 months prior to screening Known thrombophilic conditions (e.g., antiphospholipid syndrome, protein C/S deficiency, ATIII deficiency) Severe hepatic impairment (ALT or AST >3×ULN, or total bilirubin >1.5×ULN) Severe renal impairment (creatinine clearance <30 mL/min) New York Heart Association (NYHA) functional class III or IV heart failure Malignancy within 5 years prior to screening (except non-melanoma skin cancer, cervical carcinoma in situ, or ductal carcinoma in situ of the breast) Pregnancy or breastfeeding Participation in another interventional clinical trial within 30 days prior to screening Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study

Helyszínek itt: Kína

  • The First Affiliated Hospital of Soochow UniversitySuzhou, KínaContact: The First Affiliated Hospital of Soochow UniversityRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a prospective, multicenter, open-label, single-arm cohort study to evaluate the effectiveness and safety of romiplostim in patients with immune thrombocytopenia (ITP) who have not responded to oral thrombopoietin receptor agonists (TPO-RAs) such as eltrombopag, hetrombopag, or avatrombopag.

A teljes eredeti leírásKevesebb

ITP is a blood disorder in which the immune system attacks and destroys the body's own platelets, leading to low platelet counts and an increased risk of bleeding. While oral TPO-RAs are effective for many patients, approximately 20-30% of patients do not respond adequately or lose response over time. For these patients, alternative treatments are urgently needed.

Participants in this study will discontinue their current oral TPO-RA and receive romiplostim as a weekly subcutaneous injection. The starting dose is 3 µg/kg, and the dose may be adjusted weekly based on platelet counts (maximum 10 µg/kg). The total treatment and follow-up period is 24 weeks.

The primary outcome measure is the durable platelet response rate at week 24, defined as maintaining platelet counts at ≥50×10⁹/L for at least two scheduled visits during weeks 22-24 without rescue therapy. Secondary outcomes include the sustained response rate at week 12, complete response rate at week 24, time to first response, improvement in bleeding events, and quality of life assessment.

Safety outcomes include monitoring for thromboembolic events, bone marrow fibrosis, hepatotoxicity, injection site reactions, and other adverse events according to CTCAE v5.0.

Approximately 60 participants will be enrolled across multiple centers in China. This study aims to provide evidence for romiplostim as a treatment option for ITP patients who have failed oral TPO-RAs.

A vizsgálat csoportja

  • Romiplostim Treatment ArmA vizsgált kezelés

    Kezelés: Romiplostim

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective Cohort Study of Romiplostim in Immune Thrombocytopenia Patients Resistant to Oral Thrombopoietin Receptor Agonists
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. május 28.